Patients with CACP have used non-steroidal anti-inflammatory medications to seek symptom relief, which suggests that inflammation may play a role in the lubricin-null joint pathology that hitherto was thought to be a non-inflammatory arthropathy. This evidence concerns the gene PRG4 and camptodactyly-arthropathy-coxa vara-pericarditis syndrome.